Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford has entered into a strategic collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Close up of hand pipetting in lab © Medical Sciences Division and John Cairns

Through the collaboration, Oxford academics, including Kennedy Investigators Profs. Fiona Powrie and Christopher Buckley, and Dr Brian Marsden, will work with Janssen scientists to develop a cellular map of genes and proteins implicated across a range of immune-mediated inflammatory disorders and characterise pharmacologically relevant therapeutic targets. The agreement was facilitated by Johnson & Johnson Innovation.

Lead Oxford investigator for the project, Professor Holm Uhlig (Nuffield Department of Medicine) said, “This exciting endeavour brings together a world leading group of Janssen and Oxford scientists to form the Cartography collaboration. This project aims to create a detailed cellular map across multiple immune disorders which has the potential to advance the understanding of disease mechanisms, how to treat the right patients with the right medications, and the development of new therapies.”

Speaking of the partnership, Professor Fiona Powrie said, “The Oxford/Janssen collaboration is an extremely exciting initiative. It offers a unique opportunity to define the cellular basis of disease, to identify shared and unique processes across different inflammatory diseases informing the development of personalised medicine approaches.”

Immune mediated inflammatory disorders affect a large proportion of the population. Genetic association studies, functional studies, and clinical observations suggest that there is substantial overlap between immune mediated inflammatory disorders affecting different organ systems, but the cellular mechanisms are largely unknown.

This 3-year data-driven study, will apply the latest molecular and cellular multiomics analysis platforms, and computational methods to deliver insights for target selection and precision medicine for inflammatory disease indications of the intestine, the joint and the skin where existing options for therapeutic intervention are limited. The collaboration will create four new postdoctoral positions at the University of Oxford. 

Similar stories

3,400 different medicines used globally to treat COVID-19

Main Statistics and epidemiology

Insufficient data, and misleading recommendations led to significant early heterogeneity in global COVID-19 patient management, according to recent BMJ study

Clinical trial finds Azithromycin has no benefit against COVID-19

Main OCTRU

A clinical trial by University of Oxford researchers has confirmed that the antibiotic azithromycin has no clinical benefit in people with moderate COVID-19.

Study reveals the three most important aspects of care for hip fractures

Hip Main OCTRU Research Trauma

Older patients with hip fractures recover better if they receive treatment under the supervision of both a surgeon and a specialist in elderly care; are checked to avoid future falls; and are assessed for memory problems.

Major ERC funding awarded to Professor Michael Dustin

Awards Kennedy Main

Professor Michael Dustin and an international team of collaborators have been awarded a €10M grant from the European Research Council (ERC) to develop a new biotechnology around supramolecular attack particles (SMAPs) engineered to kill cancer cells.

The role of mAbs (neutralising monoclonal antibodies) in the fight against COVID-19

Main Research

Neutralising mAbs, a form of anti-viral medicine, are being explored as an attractive option to treat symptoms of COVID-19 and in some cases prevent infection. But what are the pros and cons of this type of treatment and what should regulators consider before granting approval?

Professor Michael Dustin elected to the National Academy of Sciences

Awards Kennedy Main

Recognised for his outstanding contributions to the field of immunology, Michael becomes the fourth Kennedy professor to be elected to the Academy.